| Literature DB >> 35678528 |
Julia L Drewes1, Jie Chen2, Nicholas O Markham3,4, Franck Housseau5,6, Ken S Lau4,7,8, Cynthia L Sears1,2,5,6, Reece J Knippel1, Jada C Domingue1, Ada J Tam5,6, June L Chan1, Lana Kim1, Madison McMann1, Courtney Stevens1, Christine M Dejea1, Sarah Tomkovich9, John Michel5,6, James R White10, Fuad Mohammad1, Victoria L Campodónico1, Cody N Heiser4,7, Xinqun Wu1, Shaoguang Wu1, Hua Ding2, Patricia Simner11, Karen Carroll1,11, Martha J Shrubsole8,12, Robert A Anders11, Seth T Walk13, Christian Jobin9,14,15, Fengyi Wan6,16, Robert J Coffey3,4,8.
Abstract
Defining the complex role of the microbiome in colorectal cancer and the discovery of novel, protumorigenic microbes are areas of active investigation. In the present study, culturing and reassociation experiments revealed that toxigenic strains of Clostridioides difficile drove the tumorigenic phenotype of a subset of colorectal cancer patient-derived mucosal slurries in germ-free ApcMin/+ mice. Tumorigenesis was dependent on the C. difficile toxin TcdB and was associated with induction of Wnt signaling, reactive oxygen species, and protumorigenic mucosal immune responses marked by the infiltration of activated myeloid cells and IL17-producing lymphoid and innate lymphoid cell subsets. These findings suggest that chronic colonization with toxigenic C. difficile is a potential driver of colorectal cancer in patients. SIGNIFICANCE: Colorectal cancer is a leading cause of cancer and cancer-related deaths worldwide, with a multifactorial etiology that likely includes procarcinogenic bacteria. Using human colon cancer specimens, culturing, and murine models, we demonstrate that chronic infection with the enteric pathogen C. difficile is a previously unrecognized contributor to colonic tumorigenesis. See related commentary by Jain and Dudeja, p. 1838. This article is highlighted in the In This Issue feature, p. 1825. ©2022 The Authors; Published by the American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35678528 PMCID: PMC9357196 DOI: 10.1158/2159-8290.CD-21-1273
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272